In this study, the clinical benefits (OS) of anti-CTLA-4 and anti-PD-1 therapies in patients with MAP2K1/2-mutated melanoma were compared in a pooled cohort comprising a combination of six cohorts. Here, MAP2K1 is linked to melanoma.